Skip to main content
Premium Trial:

Request an Annual Quote

Vermillion Reports OVA1 Tests Performed in 2010 Exceeds Guidance

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Vermillion today said that it had performed an estimated 6,155 of its triage ovarian cancer test for 2010, exceeding its guidance of 5,000 to 5,500 tests for the year.

In the fourth quarter, the Austin, Texas-based molecular diagnostics firm performed about 2,935 OVA1 tests, representing a 49 percent increase from the third quarter. The OVA1 test received clearance from the US Food and Drug Administration in late 2009 and was launched in March 2010.

The company also said that as of Dec. 31, 2010, it had $22.8 million in cash and cash equivalents, compared to $25.3 million at the end of the third quarter.

Vermillion will report its fourth quarter and full-year 2010 earnings results on Feb. 10.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.